59.6% of Gilenya patients achieve NEDA in study
Posted: Thu May 04, 2017 2:22 am
Novartis has announced the results of a phase IV multiple sclerosis (MS) clinical outcomes and MRI study in the US. It confirmed the effectiveness of Gilenya (fingolimod) in a real-world setting, supporting previous findings from phase III trials...Read more - http://www.ms-uk.org/75-gilenya-patient ... udy-040517